Literature DB >> 30363855

Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Susanna Jakobson Mo1, Jan Linder2, Lars Forsgren2, Katrine Riklund1.   

Abstract

Dopamine transporter (DaT) imaging may be supportive in the initial clinical diagnostic workup in patients with suspected parkinsonian diseases, given that the method has the potential to detect dopaminergic degeneration. We investigated the diagnostic accuracy of visual assessment of the initial DaT single-photon emission CT (DaT-SPECT) with 123I-FP-CIT in a large group of early-stage parkinsonian patients. After inclusion in a long-term multidisciplinary population-based prospective study, a baseline DaT-SPECT was done in 171 incidental, L-dopa-naïve, parkinsonian patients (102 men and 69 women) and 37 healthy controls (19 men and 18 women). The results of the DaT-SPECTs were linked to criteria-based clinical diagnoses, which were set after a mean follow-up of 4.6 (±1.7) years. The outcome of the visual assessment was also compared with that of a semiquantitative evaluation method using regions of interest to measure uptake ratios in the caudate and putamen. We found that visual assessment of DaT-SPECT in clinically diagnosed incidental Parkinson's disease patients had a sensitivity of 94% and a specificity of 92%, rendering a positive likelihood ratio of 11.75 and a negative likelihood ratio of 0.07. The proportion of false positives was 1.4% and false negatives 4.8% at baseline. These figures were comparable to those of the semiquantitative method. This study demonstrates that visual interpretation of presynaptic dopamine imaging with 123I-FP-CIT offers reliable support in the diagnostic procedure of early parkinsonian diseases.

Entities:  

Keywords:  dopamine transporter; parkinsonism; sensitivity; single‐photon emission CT; specificity

Year:  2014        PMID: 30363855      PMCID: PMC6182987          DOI: 10.1002/mdc3.12089

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  30 in total

1.  How valid is the clinical diagnosis of Parkinson's disease in the community?

Authors:  K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

2.  Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies.

Authors:  Nikolaos Papathanasiou; Phivi Rondogianni; Panagiota Chroni; Marios Themistocleous; Efstathios Boviatsis; Xanthi Pedeli; Damianos Sakas; Ioannis Datseris
Journal:  Ann Nucl Med       Date:  2012-01-12       Impact factor: 2.668

3.  Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.

Authors:  Laura D Perju-Dumbrava; Gabor G Kovacs; Susanne Pirker; Kurt Jellinger; Martha Hoffmann; Susanne Asenbaum; Walter Pirker
Journal:  Mov Disord       Date:  2011-11-18       Impact factor: 10.338

Review 4.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

5.  Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.

Authors:  Vicky L Marshall; Jim Patterson; Donald M Hadley; Katherine A Grosset; Donald G Grosset
Journal:  Nucl Med Commun       Date:  2006-12       Impact factor: 1.690

6.  Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study.

Authors:  Petra Schwingenschuh; Diane Ruge; Mark J Edwards; Carmen Terranova; Petra Katschnig; Fatima Carrillo; Laura Silveira-Moriyama; Susanne A Schneider; Georg Kägi; Francisco J Palomar; Penelope Talelli; John Dickson; Andrew J Lees; Niall Quinn; Pablo Mir; John C Rothwell; Kailash P Bhatia
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

7.  Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Authors:  Vicky L Marshall; Cornelia B Reininger; Moritz Marquardt; Jim Patterson; Donald M Hadley; Wolfgang H Oertel; Hani T S Benamer; Paul Kemp; David Burn; Eduardo Tolosa; Jamie Kulisevsky; Luis Cunha; Durval Costa; Jan Booij; Klaus Tatsch; K Ray Chaudhuri; Gudrun Ulm; Oliver Pogarell; Helmut Höffken; Anja Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

Review 9.  SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

Authors:  Jan Booij; Remco J J Knol
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

Review 10.  Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.

Authors:  Nin Bajaj; Robert A Hauser; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

View more
  3 in total

1.  Reply to Comment on: Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Authors:  Srivadee Oravivattanakul; Lucas Benchaya; Anwar Ahmed; Ilia Itin; Scott Cooper; Michal Gostkowski; Joseph Rudolph; Kristin Appleby; Patrick Sweeney; Hubert H Fernandez; Guiyun Wu
Journal:  Mov Disord Clin Pract       Date:  2016-07-28

Review 2.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

Review 3.  Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT.

Authors:  Balestrino Roberta; Barone Paolo; Filippi Massimo; Erro Roberto
Journal:  J Neurol       Date:  2021-09-18       Impact factor: 6.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.